These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15215494)

  • 41. The risks and incidence of K65R and L74V mutations and subsequent virologic responses.
    Waters L; Nelson M; Mandalia S; Bower M; Powles T; Gazzard B; Stebbing J
    Clin Infect Dis; 2008 Jan; 46(1):96-100. PubMed ID: 18171220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
    J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current world literature.
    Curr Opin HIV AIDS; 2010 May; 5(3):261-3. PubMed ID: 20539084
    [No Abstract]   [Full Text] [Related]  

  • 44. [Resistance to protease inhibitors: the burden of mutations].
    Marcelin AG
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S198-205. PubMed ID: 17075997
    [No Abstract]   [Full Text] [Related]  

  • 45. HIV drug resistance.
    Clavel F; Hance AJ
    N Engl J Med; 2004 Mar; 350(10):1023-35. PubMed ID: 14999114
    [No Abstract]   [Full Text] [Related]  

  • 46. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
    Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
    Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
    Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
    Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining evidence for access to and benefits from antiretroviral treatment to inform planning.
    ; Marlink R; Forsythe S; Bertozzi SM; Muirhead D; Holmes M; Sturchio J
    AIDS; 2008 Jul; 22 Suppl 1():S121-2. PubMed ID: 18664943
    [No Abstract]   [Full Text] [Related]  

  • 50. Antiretroviral therapy: where are we?
    Hammer SM; Yeni P
    AIDS; 1998; 12 Suppl A():S181-8. PubMed ID: 9633001
    [No Abstract]   [Full Text] [Related]  

  • 51. [Rates of primary antiretroviral drug resistance in patients diagnosed with HIV infection in Gran Canaria in 2006-2008].
    Hernández-Febles M; Zarzalejos-Andés JM; Cárdenes-Santana MA; Pena-López MJ
    Enferm Infecc Microbiol Clin; 2010; 28(6):392-3. PubMed ID: 20096974
    [No Abstract]   [Full Text] [Related]  

  • 52. Resistance to antiviral drugs is climbing.
    Kmietowicz Z
    BMJ; 2005 Aug; 331(7512):308. PubMed ID: 16081434
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinton brokers deal to lower price of antiretrovirals.
    Abimbola S
    BMJ; 2007 May; 334(7602):1026. PubMed ID: 17510129
    [No Abstract]   [Full Text] [Related]  

  • 54. Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention.
    Gayle H; Lange JM
    Lancet; 2004 Jul 3-9; 364(9428):6-8. PubMed ID: 15234835
    [No Abstract]   [Full Text] [Related]  

  • 55. Call for action to secure universal access to ART in developing countries.
    Orsi F; Carrieri MP; Coriat B; Delaporte E; Moatti JP; Spire B; Taverne B; Barré-Sinoussi F
    Lancet; 2010 May; 375(9727):1693-4. PubMed ID: 20472168
    [No Abstract]   [Full Text] [Related]  

  • 56. Disease management--constructing optimal NRTI-based combinations: past, present, and future.
    Dieterich DT
    MedGenMed; 2006 Jan; 8(1):16. PubMed ID: 16915146
    [No Abstract]   [Full Text] [Related]  

  • 57. Modeling the impact of antiretroviral use in developing countries.
    Bertozzi SM; Bautista-Arredondo S
    PLoS Med; 2006 Apr; 3(4):e148. PubMed ID: 16522134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV groups call on US government to fund preventive drug treatment.
    Roehr B
    BMJ; 2011 Aug; 343():d5412. PubMed ID: 21865272
    [No Abstract]   [Full Text] [Related]  

  • 59. HIV/AIDS: the private sector is vital.
    England R
    Lancet; 2004 Sep 18-24; 364(9439):1033-4. PubMed ID: 15380956
    [No Abstract]   [Full Text] [Related]  

  • 60. Current world literature.
    Curr Opin HIV AIDS; 2013 Jan; 8(1):75-85. PubMed ID: 23211780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.